ResearcherUniversitätsmedizin GöttingenActive in the last 2 years
Ulrich Sax
Matched on ORCID iD 0000-0002-8188-3495; OpenAlex author ID A5013507281. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 39
2024: 2 papers · 2025: 2 papers · 2026: 2 papers
Papers 6
- GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Co-author DOI 10.1136/gutjnl-2025-336227↗
- Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-026-02628-3↗
- KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
- TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Co-author DOI 10.1126/sciadv.adu2339↗
- An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
- A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys. Last author DOI 10.3233/shti240862↗
Closest collaborators
The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisabeth Heßmann · 6 shared papers, 2024–2026 · strength 1.11
- Paper TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. DOI 10.1126/sciadv.adu2339↗
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Paper A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys. DOI 10.3233/shti240862↗
- Volker Ellenrieder · 5 shared papers, 2024–2026 · strength 0.92
- Paper TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. DOI 10.1126/sciadv.adu2339↗
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Paper A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys. DOI 10.3233/shti240862↗
- Günter Schneider · 4 shared papers, 2024–2026 · strength 0.70
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Paper Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-026-02628-3↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Michael B. Ghadimi · 3 shared papers, 2025–2026 · strength 0.58
- Paper TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. DOI 10.1126/sciadv.adu2339↗
- Paper Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-026-02628-3↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Lena‐Christin Conradi · 3 shared papers, 2025–2026 · strength 0.56
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Paper Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-026-02628-3↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Shiv K. Singh · 3 shared papers, 2024–2026 · strength 0.56
- Paper TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. DOI 10.1126/sciadv.adu2339↗
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Paper An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. DOI 10.1053/j.gastro.2023.10.026↗
- Carolin Schneider · 3 shared papers, 2024–2026 · strength 0.49
- Paper Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-026-02628-3↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Paper An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. DOI 10.1053/j.gastro.2023.10.026↗
- Lukas Klein · 2 shared papers, 2025–2026 · strength 0.42
- Paper TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. DOI 10.1126/sciadv.adu2339↗
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Jonas Hügel · 2 shared papers, 2024–2025 · strength 0.36
- Tiago De Oliveira · 2 shared papers, 2025–2026 · strength 0.36
- Steven A. Johnsen · 2 shared papers, 2024–2026 · strength 0.34
- Paper GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induct… DOI 10.1136/gutjnl-2025-336227↗
- Paper An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. DOI 10.1053/j.gastro.2023.10.026↗
- Christoph Ammer‐Herrmenau · 2 shared papers, 2024 · strength 0.33
- Alexander Otto König · 2 shared papers, 2024 · strength 0.33
- Maximilian Reichert · 2 shared papers, 2024–2025 · strength 0.30
- Ramona Schulz‐Heddergott · 1 shared paper, 2025 · strength 0.22
- Laura Urbach · 1 shared paper, 2025 · strength 0.22
- Rebecca Diya Samuel · 1 shared paper, 2025 · strength 0.22
- Nelson Dusetti · 1 shared paper, 2025 · strength 0.22
- Muhammad Umair Latif · 1 shared paper, 2026 · strength 0.20
- Oliver Holger Krämer · 1 shared paper, 2026 · strength 0.20
- Zeynab Najafova · 1 shared paper, 2026 · strength 0.20
- Argyris Papantonis · 1 shared paper, 2026 · strength 0.19
- Alexandra Maria Schmitt · 1 shared paper, 2026 · strength 0.19
- Nathalia Luisa Carlos Ferreira · 1 shared paper, 2026 · strength 0.19
- Christian Schneeweis · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.